KALY Cannabis Pharma News Lights Up PPS Ready To Run From $0.01 to $0.04 On Way To $0.10
April 03 2019 - 11:43AM
InvestorsHub NewsWire
KALY Cannabis Pharma News Lights Up
PPS Ready To Run From $0.01 to $0.04 On Way To $0.10
New York, NY -- April 3, 2019
-- InvestorsHub NewsWire -- www.nextbigticker.com --
Kali-Extracts, Inc. (USOTC:
KALY) revealed yesterday for the first time ongoing patented
cannabis extract Type 2 Diabetes Treatment research the company
had previously kept under wraps adding to the recently published
research results from the company’s pilot Chronic Obstructive Pulmonary Disease (COPD)
treatment evaluation. The press release yesterday indicated two
more cannabis extract health issue treatments are also soon to be
revealed. KALY trading has shot to the OTC top 25 most
actively traded list with the PPS edging toward a breakout.
The PPS is above the 200 Day MA and has now broken past the 50 Day
MA following a MACD cross. The candlestick analysis is
indicating VERY BULLISH.
“The market is finally giving hints of a bullish
resurgence. Today a bullish pattern is
detected. “
AmericanBulls.com
KALY Potential PPS Run From $0.01 to $0.04 On
Way To $0.10
KALY
has the potential to run from its $0.01 PPS level to $0.10 in the
near term. Shortly after the 2018 Q4 acquisition of the patented
cannabis extraction process, the company PPS shot from sub-penny
land to almost $0.04 on volume that put it in the top 20 most
actively traded stocks on the OTC Market. The PPS retraced back to
$0.01 and has been holding that price with a healthy trading
volume. With KALY’s patented cannabis pharmaceutical research
now coming to light, the PPS is positioned to shoot past the recent
$0.04 highs to a level putting it on par with some of the other
penny cannabis stock contenders. A $0.10 PPS is a reasonable
milestone following the company filing its upcoming annual reported
expected to include the company posting its first revenue derived
from its cannabis extraction process. The company filed an
extension on the 2018 annual report with the report itself now
expected within the next 15 days.
KALY is
providing CBD extracts for over $1 million worth of CBD infused
water produced by Puration, Inc. (USOTC:
PURA), and KALY has also introduced its own CBD infused
gum. KALY is also implementing an extraction lab to process
biomass from Nouveau’s (USOTC:
NOUV) 100 acred hemp farm.
Following the acquisition of the patented
cannabis extraction process late last year and the corresponding
jump in price and trading volume, the OTC Markets flagged the
company in response to the jump in activity. The company has
responded by updating all its OTC Markets required reports.
Management is likely to mitigate the OTC Market’s concerns sooner
or later and see the flag removed which will likely be yet another
impetus fueling a KALY PPS run.
Management engaged Goldman Small Cap Research to
conduct analyst coverage of the company and file an initial analyst
report: KALY Research
Report
Disclaimer/Safe Harbor:
This
news release contains forward-looking statements within the meaning
of the Securities Litigation Reform Act. The statements reflect the
Company's current views with respect to future events that involve
risks and uncertainties. Among others, these risks include the
expectation that any of the companies mentioned herein will achieve
significant sales, the failure to meet schedule or performance
requirements of the companies' contracts, the companies' liquidity
position, the companies' ability to obtain new contracts, the
emergence of competitors with greater financial resources and the
impact of competitive pricing. In the light of these uncertainties,
the forward-looking events referred to in this release might not
occur.
Source: www.nextbigticker.com
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024